Soligenix, Inc. Common Stock

Day range

$0.35 – $0.37

Open

$0.37

Prev close

$0.37

Volume

32.52K

Market cap

$7.94M

Shares out

21.77M

P/E

—

P/S

—

P/B

1.21

P/FCF

—

ROE

-154.1%

ROA

-97.5%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Underwriting agreementSep 21, 2026

  “the At Market Issuance Sales Agreement, dated January 23, 2026 … with Rodman & Renshaw LLC.”

• Public offeringJun 26, 2026

  On June 26, 2026, Soligenix, Inc. (the "Company") filed a prospectus supplement (the "Current Prospectus Supplement") to increase the maximum aggregate offering amount of the shares of the Company's common stock, par value $0.001 per share, issuable under the At Market Issuance Sales Agreement, dated January 23, 2026 (the "Sales Agreement"), with Rodman & Renshaw LLC, by an additional aggregate amount of $2,500,000.

• Executive officer departureJun 12, 2026

  On June 11, 2026, in connection with the Company's decision to terminate the HyBryte™ development program, Dr. Straube ceased serving as the Company's Consulting Chief Medical Officer. The Company and Dr. Straube have agreed that Dr. Straube will continue to be available to consult with the Company on an as-needed, hourly basis.

• Public offeringMay 28, 2026

  On May 28, 2026, Soligenix, Inc. (the "Company") filed a prospectus supplement (the "Current Prospectus Supplement") to increase the maximum aggregate offering amount of the shares of the Company's common stock, par value $0.001 per share, issuable under the At Market Issuance Sales Agreement dated January 23, 2026 (the "Sales Agreement") with Rodman & Renshaw LLC, by an additional aggregate amount of $2,956,000.

• Clinical trial resultsApr 28, 2026

  On April 28, 2026, Soligenix, Inc. (the "Company") issued a press release announcing the interim results from the Phase 3 FLASH2 (Fluorescent Light Activated Synthetic Hypericin 2) trial evaluating HyBryte™ (Synthetic Hypericin) in the treatment of cutaneous T-cell lymphoma. Under the terms of the interim efficacy analysis conducted by the Data Monitoring Committee, the study was recommended to halt for futility.

Days to cover

1.0

Short interest

168.05K

Avg volume

309.47K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine
  positiveBenzinga· Jun 8, 2026
• Soligenix (SNGX) Stock Soars 72% On ThermoVax Platform Promise Amid Ebola Outbreak Caused By Bundibugyo Virus
  positiveBenzinga· May 27, 2026
• Cutaneous T-Cell Lymphoma Clinical Trial Pipeline Accelerates as 30+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsight
  positiveGlobeNewswire Inc.· May 21, 2026
• The Psoriasis Clinical Trial Pipeline Boom as 90+ Companies are in the Race for Better Treatments | DelveInsight
  positiveGlobeNewswire Inc.· Apr 14, 2026
• Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy
  positiveBenzinga· Apr 2, 2026